QQ客服 官方微博 反馈留言

	Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
	Song Wenbin; He Dalin; Chen Yule; Yeh Chiuan-Ren; Hsu Iawen; Huang Qingbo; Zhang Xu; Chang Luke Sien-Shih; Zuo Li; Chen Jiasheng
刊名	Molecular oncology
	2018
卷号	12页码:2055-2071
关键词	selective estrogen receptor modulator tamoxifen ICI 182,780 epithelial-mesenchymal transition estrogen receptor &beta TGF&beta
ISSN号	1878-0261
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2918943
专题	西安交通大学
推荐引用方式 GB/T 7714	Song Wenbin,He Dalin,Chen Yule,et al. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.[J]. Molecular oncology,2018,12:2055-2071.
APA	Song Wenbin.,He Dalin.,Chen Yule.,Yeh Chiuan-Ren.,Hsu Iawen.,...&Yeh Shuyuan.(2018).Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma..Molecular oncology,12,2055-2071.
MLA	Song Wenbin,et al."Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.".Molecular oncology 12(2018):2055-2071.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。